

PATIENT NAME: PRANAVKUMAR S. RANA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138364

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0321WG001445

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: ABHA NO : AGE/SEX : DRAWN :

RECEIVED : 08/07/2023 08:55:50 REPORTED :10/07/2023 17:59:14

:31 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

ECG

ECG NORMAL SINUS RHYTHM

MEDICAL HISTORY

RELEVANT PRESENT HISTORY

RELEVANT PAST HISTORY

RELEVANT PERSONAL HISTORY

NOT SIGNIFICANT

NOT SIGNIFICANT

RELEVANT FAMILY HISTORY DIABETES

OCCUPATIONAL HISTORY NOT SIGNIFICANT HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.62 mts WEIGHT IN KGS. 77.3 Kgs

BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL
PHYSICAL ATTITUDE NORMAL
GENERAL APPEARANCE / NUTRITIONAL OVERWEIGHT

STATUS

BUILT / SKELETAL FRAMEWORK AVERAGE
FACIAL APPEARANCE NORMAL
SKIN NORMAL
UPPER LIMB NORMAL
LOWER LIMB NORMAL
NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

TEMPERATURE NORMAL

P V Kapadia

Dr. Priyank Kapadia

Physician

Dr.Jinal kamodia Consultant Radiology



Page 1 Of 21

View Details

View Report







PATIENT NAME: PRANAVKUMAR S. RANA

CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0321WG001445

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

REF. DOCTOR: SELF

:31 Years

RECEIVED: 08/07/2023 08:55:50 REPORTED :10/07/2023 17:59:14

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

88/MIN **PULSE NORMAL** RESPIRATORY RATE

CARDIOVASCULAR SYSTEM

BP 130/84 MM HG mm/Hg

(SITTING)

PERICARDIUM NORMAL APEX BEAT **NORMAL**

HEART SOUNDS S1, S2 HEARD NORMALLY

ABSENT MURMURS

RESPIRATORY SYSTEM

NORMAL SIZE AND SHAPE OF CHEST MOVEMENTS OF CHEST SYMMETRICAL BREATH SOUNDS INTENSITY **NORMAL**

VESICULAR (NORMAL) BREATH SOUNDS QUALITY

ADDED SOUNDS **ABSENT**

PER ABDOMEN

APPEARANCE NORMAL **LIVER NOT PALPABLE**

SPLEEN NOT PALPABLE

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS **NORMAL NORMAL** CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS SENSORY SYSTEM **NORMAL NORMAL** MOTOR SYSTEM **NORMAL** RFFI FXFS

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

DISTANT VISION RIGHT EYE WITHOUT 6/9

GLASSES

P V Espadia

Dr. Priyank Kapadia

Physician

Dr.Jinal kamodia

Page 2 Of 21

Consultant Radiology









CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321WG001445 AGE/SEX :31 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 08/07/2023 08:55:50

REPORTED :10/07/2023 17:59:14

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

6/12 DISTANT VISION LEFT EYE WITHOUT

GLASSES

NEAR VISION RIGHT EYE WITHOUT GLASSES N/6 NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION **NORMAL**

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS **NOT SIGNIFICANT**

RELEVANT LAB INVESTIGATIONS S.CHOLESTEROL:- HIGH, TRIGLYCERIDES:- HIGH, HDL:- LOW, LDL:-

HIGH, VLDL:- HIGH

SGPT:- HIGH, SGOT:- HIGH

URIC ACID:- HIGH

NO ABNORMALITIES DETECTED RELEVANT NON PATHOLOGY DIAGNOSTICS

1) S.CHOLESTEROL:- HIGH, TRIGLYCERIDES:- HIGH, HDL:- LOW, LDL:-REMARKS / RECOMMENDATIONS

HIGH, VLDL:- HIGH, SGPT:- HIGH, SGOT:- HIGH

ADV:- LOW FAT DIET, REGULAR PHYSICAL EXERCISE

2) URIC ACID:- HIGH

ADV:- PHYSICIAN OPINION

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

CHECK UP DONE BY: - DR. NAMRATA AGRAWAL (M.B.B.S)

REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST: - DR. SAHIL N SHAH (M.D.RADIOLOGY) / DR. J. S. KAMODIA (M. D. RADIOLOGY)

P V Kapadia

Dr. Priyank Kapadia **Physician**

Dr.Jinal kamodia **Consultant Radiology**





Page 3 Of 21





PATIENT NAME: PRANAVKUMAR S. RANA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO : 0321WG001445 AGE/SEX

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED: 08/07/2023 08:55:50 REPORTED :10/07/2023 17:59:14

:31 Years

Test Report Status Results Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED

TMT OR ECHO

TMT OR ECHO

2D ECHO:-

- 1) NORMAL CHAMBERS AND VALVES.
- 2) GOOD LV SYSTOLIC FUNCTION. LVEF 65%. NO RWMA AT REST.
- 3) NO MR, AR, TR.
- 4) NORMAL LV COMPLIANCE.
- 5) NO PAH.
- 6) NO LV CLOT, VEGETATION OR PERICARDIAL EFFUSION.
- 7) IAS/IVS INTACT.

Interpretation(s)
MEDICAL
HISTORY-*******

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

P V Espadia

Dr.Priyank Kapadia **Physician**

Dr.Jinal kamodia **Consultant Radiology**





Page 4 Of 21

Email: customercare.ahmedabad@agilus.in





CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

CLIENT PATIENT ID: ABHA NO

ACCESSION NO: 0321WG001445 AGE/SEX :31 Years

PATIENT ID : PRANM291291321 DRAWN

RECEIVED: 08/07/2023 08:55:50 REPORTED :10/07/2023 17:59:14

Biological Reference Interval Test Report Status Results Units <u>Final</u>

į.	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP B	ELOW 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: PHOTOMETRIC MEASUREMENT	16.0	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: COULTER PRINCIPLE	5.20	4.5 - 5.5	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: COULTER PRINCIPLE	5.50	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: COULTER PRINCIPLE	366	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED	47.6	40.0 - 50.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	91.5	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED	30.8	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED	33.7	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM	12.7	11.6 - 14.0	%
MENTZER INDEX METHOD: CALCULATED PARAMETER	17.6		
MEAN PLATELET VOLUME (MPV) METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM	7.4	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD: OPTICAL IMPEDENCE & MICROCSOPY	42	40 - 80	%
LYMPHOCYTES	48 High	20 - 40	%
METHOD: OPTICAL IMPEDENCE & MICROCSOPY			
MONOCYTES METHOD: OPTICAL IMPEDENCE & MICROCSOPY	7	2.0 - 10.0	%
EOSINOPHILS	2	1.0 - 6.0	%

Dr.Miral Gajera Consultant Pathologist



Page 5 Of 21





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0321WG001445 AGE/SEX :31 Years

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: RECEIVED: 08/07/2023 08:55:50 ABHA NO REPORTED :10/07/2023 17:59:14

Test Report Status <u>Final</u>	Results	Biological Reference Interva	al Units
METHOD : OPTICAL IMPEDENCE & MICROCSOPY			
BASOPHILS	1	0 - 1	%
METHOD: IMPEDANCE			
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED	2.31	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.64	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.39	0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.11	0.02 - 0.50	thou/µL
METHOD: CALCULATED			
ABSOLUTE BASOPHIL COUNT	0.06	0.02 - 0.10	thou/µL
METHOD: CALCULATED			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	0.9		
METHOD: CALCULATED PARAMETER			
MORPHOLOGY			
RBC	NORMOCYTIC NORMOCHRO	OMIC	
METHOD: MICROSCOPIC EXAMINATION			
WBC	NORMAL MORPHOLOGY		
METHOD: MICROSCOPIC EXAMINATION			
PLATELETS	ADEQUATE		
METHOD: MICROSCOPIC EXAMINATION			
REMARKS	NO PREMATURE CELLS AND DETECTED.	RE SEEN. MALARIAL PARASITE N	ОТ

METHOD: MICROSCOPIC EXAMINATION

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera Consultant Pathologist





Page 6 Of 21







CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0321WG001445 AGE/SEX :31 Years

PATIENT ID : PRANM291291321 DRAWN

CLIENT PATIENT ID: RECEIVED: 08/07/2023 08:55:50 REPORTED :10/07/2023 17:59:14 ABHA NO

Test Report Status Biological Reference Interval Final Results Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

0 - 14mm at 1 hr E.S.R

METHOD: WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 5.0 Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 96.8 < 116.0 mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.3. Identifying patients at increased risk for diabetes (prediabetes).

Dr.Miral Gajera Consultant Pathologist





Page 7 Of 21





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321WG001445 AGE/SEX :31 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID : PRANM291291321

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 08/07/2023 08:55:50 DELHI ABHA NO REPORTED :10/07/2023 17:59:14 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** <u>Final</u> Units

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.Miral Gajera Consultant Pathologist



Page 8 Of 21



Patient Ref. No. 775000003830052

Email: customercare.ahmedabad@agilus.in



CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321WG001445 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

: PRANM291291321 CLIENT PATIENT ID:

ABHA NO

AGE/SEX DRAWN

RECEIVED: 08/07/2023 08:55:50

:31 Years

REPORTED :10/07/2023 17:59:14

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE O **ABO GROUP**

METHOD: TUBE AGGLUTINATION

RH TYPE **POSITIVE**

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera Consultant Pathologist

Page 9 Of 21



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India

Email: customercare.ahmedabad@agilus.in



CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0321WG001445

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

RECEIVED: 08/07/2023 08:55:50 REPORTED :10/07/2023 17:59:14

:31 Years

Biological Reference Interval Test Report Status Results Units <u>Final</u>

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECK UP	BELOW 40 MALE		
GLUCOSE FASTING,FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD: HEXOKINASE	92	74 - 99	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD: HEXOKINASE	93	70 - 140	mg/dL
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	249 High	Desirable: < 200 BorderlineHigh: 200 - 239 High: > or = 240	mg/dL
METHOD: ENZYMATIC, COLORIMETRIC		_	
TRIGLYCERIDES	187 High	Desirable: < 150 BorderlineHigh: 150 - 199 High: 200 - 499 Very High: > or = 500	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC		, 5	
HDL CHOLESTEROL	37 Low	< 40 Low > or = 60 High	mg/dL
CHOLESTEROL LDL	175 High	Adult levels: Optimal < 100 Near optimal/above optima 100-129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL I:
NON HDL CHOLESTEROL	212 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	37.4 High	< or = 30	mg/dL
CHOL/HDL RATIO	6.7 High	3.3 - 4.4	
LDL/HDL RATIO	4.7 High	0.5 - 3.0 Desirable/Low Ris 3.1 - 6.0 Borderline/Modera Risk >6.0 High Risk	

Dr.Miral Gajera Consultant Pathologist





Page 10 Of 21



Tel: 079-48912999,079-48913999,079-48914999 Email: customercare.ahmedabad@agilus.in

Patient Ref. No. 775000003830052



PATIENT NAME: PRANAVKUMAR S. RANA REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138364 ACCESSION NO: 0321WG001445 AGE/SEX :31 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRANM291291321 DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 08/07/2023 08:55:50 DELHI ABHA NO REPORTED :10/07/2023 17:59:14 **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

METHOD : CALCULATED

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Extreme risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease Very High Risk 1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia High Risk 1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL > 190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC > 300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque Moderate Risk 2 major ASCVD risk factors Low Risk 0-1 major ASCVD risk factors Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 2. Family history of premature ASCVD 4. High blood pressure	Risk Category			
So mg/dl or polyvascular disease	Extreme risk group	A.CAD with > 1 feature of high risk group		
Very High Risk 1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia High Risk 1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque Moderate Risk 2 major ASCVD risk factors Low Risk 0-1 major ASCVD risk factors Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C < or =	
Familial Homozygous Hypercholesterolemia High Risk 1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque Moderate Risk 2 major ASCVD risk factors Low Risk 0-1 major ASCVD risk factors Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		50 mg/dl or polyvascular disease		
High Risk 1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque Moderate Risk 2 major ASCVD risk factors Low Risk 0-1 major ASCVD risk factors Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use	Very High Risk	1. Established ASCVD 2. Diabetes with 2 1	major risk factors or evidence of end organ damage 3.	
damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque Moderate Risk 2 major ASCVD risk factors Low Risk 0-1 major ASCVD risk factors Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		Familial Homozygous Hypercholesterolemi	a	
Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque Moderate Risk 2 major ASCVD risk factors Low Risk 0-1 major ASCVD risk factors Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use	High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
Moderate Risk 2 major ASCVD risk factors Low Risk 0-1 major ASCVD risk factors Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
Low Risk 0-1 major ASCVD risk factors Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors 1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use	Moderate Risk	2 major ASCVD risk factors		
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use	Low Risk	0-1 major ASCVD risk factors		
	Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	actors	
2. Family history of premature ASCVD 4. High blood pressure	1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use		3. Current Cigarette smoking or tobacco use	
	2. Family history of premature ASCVD 4. High blood pressure		4. High blood pressure	
5. Low HDL				

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	1.27 High	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.40 High	Upto 0.2	mg/dL
METHOD: DIAZO COLORIMETRIC			
BILIRUBIN, INDIRECT	0.87	0.00 - 1.00	mg/dL
TOTAL PROTEIN	7.7	6.4 - 8.3	g/dL
METHOD: COLORIMETRIC			
ALBUMIN	4.5	3.5 - 5.2	g/dL

Dr.Miral Gajera Consultant Pathologist





Page 11 Of 21

iew Details

View Report

PERFORMED AT:

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





PATIENT NAME: PRANAVKUMAR S. RANA

CODE/NAME & ADDRESS: C000138364

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 REF. DOCTOR: SELF

ACCESSION NO: **0321WG001445**PATIENT ID: PRANM291291321

PATIENT ID : PRANM291291321 CLIENT PATIENT ID:

ABHA NO :

AGE/SEX DRAWN

RECEIVED: 08/07/2023 08:55:50

:31 Years

REPORTED :10/07/2023 17:59:14

	_ i	i	
Test Report Status <u>Final</u>	Results	Biological Reference 1	Interval Units
METHOD: BROMOCRESOL GREEN			
GLOBULIN	3.2	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	1.4	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: IFCC WITHOUT PYRIDOXAL PHOSPHATE	46 High	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: IFCC WITHOUT PYRIDOXAL PHOSPHATE	92 High	0 - 41	U/L
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	80	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	40	8 - 61	U/L
LACTATE DEHYDROGENASE	196	135 - 225	U/L
METHOD: UV ASSAY METHOD			
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	5 Low	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD: JAFFE ALKALINE PICRATE	0.72	0.70 - 1.30	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO	6.94	5.0 - 15.0	
URIC ACID, SERUM		3.0 _3.0	
URIC ACID	8.6 High	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM	-		5.
TOTAL PROTEIN METHOD: COLORIMETRIC	7.7	6.4 - 8.3	g/dL
ALBUMIN, SERUM			
ALBUMIN METHOD: BROMOCRESOL GREEN	4.5	3.5 - 5.2	g/dL
GLOBULIN			
GLOBULIN	3.2	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD: ISE	140.0	136 - 145	mmol/L
POTASSIUM, SERUM METHOD: ISE	5.08	3.3 - 5.1	mmol/L

Dr.Miral Gajera Consultant Pathologist





Page 12 Of 21

View Details

PERFORMED AT:

Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321WG001445 AGE/SEX :31 Years

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : PRANM291291321

CLIENT PATIENT ID:

DRAWN

RECEIVED: 08/07/2023 08:55:50

REPORTED :10/07/2023 17:59:14

Test Report Status Results **Biological Reference Interval Final** Units

ABHA NO

98 - 106 CHLORIDE, SERUM 103.5 mmol/L

METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy,adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea), diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadre no corticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide,salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glyosuria,Glycaemic index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin

Dr.Miral Gajera Consultant Pathologist



Page 13 Of 21



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO : 0321WG001445

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

RECEIVED: 08/07/2023 08:55:50

:31 Years

REPORTED: 10/07/2023 17:59:14

Test Report Status Results **Biological Reference Interval Final** Units

may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. **Total Protein** also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels:-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr.Miral Gajera Consultant Pathologist



Page 14 Of 21



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Guirat, India

Tel : 079-48912999,079-48913999,079-48914999 Email: customercare.ahmedabad@agilus.in

Patient Ref. No. 775000003830052



PATIENT NAME: PRANAVKUMAR S. RANA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0321WG001445

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

RECEIVED: 08/07/2023 08:55:50

:31 Years

REPORTED :10/07/2023 17:59:14

Biological Reference Interval **Test Report Status** Results Units **Final**

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR Yellow Clear **APPEARANCE**

CHEMICAL EXAMINATION, URINE

PH 6.0 4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY

SPECIFIC GRAVITY 1.015 1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY

METHOD: REFLECTANCE SPECTROPHOTOMETRY

PROTEIN NOT DETECTED **NEGATIVE**

NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY

NOT DETECTED NOT DETECTED KETONES METHOD: REFLECTANCE SPECTROPHOTOMETRY

BLOOD

NOT DETECTED **NEGATIVE** METHOD: REFLECTANCE SPECTROPHOTOMETRY

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY

UROBILINOGEN NORMAL **NORMAL**

METHOD: REFLECTANCE SPECTROPHOTOMETRY

NITRITE NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY NOT DETECTED LEUKOCYTE ESTERASE TRACE

METHOD: REFLECTANCE SPECTROPHOTOMETRY

MICROSCOPIC EXAMINATION, URINE

/HPF **NOT DETECTED** NOT DETECTED RED BLOOD CELLS

METHOD: MICROSCOPIC EXAMINATION

/HPF PUS CELL (WBC'S) 3-5 0-5

METHOD: MICROSCOPIC EXAMINATION

0-5 /HPF EPITHELIAL CELLS 3-5

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

Dr.Miral Gajera Consultant Pathologist



Page 15 Of 21



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015

Gujrat, India





PATIENT NAME: PRANAVKUMAR S. RANA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321WG001445 AGE/SEX :31 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : PRANM291291321 F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 08/07/2023 08:55:50 DELHI ABHA NO REPORTED :10/07/2023 17:59:14 **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

NOT DETECTED **CRYSTALS**

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT ON **REMARKS**

CENTRIFUGED URINARY SEDIMENT.

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,
	interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
	diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis

Dr.Miral Gajera Consultant Pathologist



Page 16 Of 21





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015





CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321WG001445 AGE/SEX :31 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

PATIENT ID : PRANM291291321

DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID:

RECEIVED: 08/07/2023 08:55:50 DELHI REPORTED :10/07/2023 17:59:14 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr.Miral Gajera Consultant Pathologist



Page 17 Of 21

Email: customercare.ahmedabad@agilus.in

Patient Ref. No. 775000003830052



CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321WG001445 AGE/SEX :31 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

PATIENT ID : PRANM291291321

CLIENT PATIENT ID:

DRAWN

RECEIVED: 08/07/2023 08:55:50

REPORTED: 10/07/2023 17:59:14

Test Report Status Results **Biological Reference Interval** Units **Final**

ABHA NO

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, STOOL

BROWN COLOUR

CONSISTENCY WELL FORMED

MUCUS NOT DETECTED NOT DETECTED

VISIBLE BLOOD ABSENT **ABSENT**

NOT DETECTED ADULT PARASITE

METHOD: MICROSCOPIC EXAMINATION

CHEMICAL EXAMINATION, STOOL

STOOL PH **NEGATIVE**

OCCULT BLOOD NOT DETECTED NOT DETECTED

METHOD: HEMOSPOT

MICROSCOPIC EXAMINATION, STOOL

PUS CELLS NOT DETECTED /hpf

NOT DETECTED **NOT DETECTED** /HPF RED BLOOD CELLS

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED **CYSTS** NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

OVA NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED NOT DETECTED **I ARVAF**

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED NOT DETECTED TROPHOZOITES

METHOD: MICROSCOPIC EXAMINATION

FAT ABSENT VEGETABLE CELLS VERY LITTLE CHARCOT LEYDEN CRYSTALS **ABSENT**

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF CONDITION

Dr.Miral Gajera Consultant Pathologist



Page 18 Of 21



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India





REF. DOCTOR: SELF PATIENT NAME: PRANAVKUMAR S. RANA CODE/NAME & ADDRESS: C000138364 ACCESSION NO: 0321WG001445 AGE/SEX :31 Years Male ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRANM291291321 DRAWN F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 08/07/2023 08:55:50 DELHI ABHA NO REPORTED: 10/07/2023 17:59:14 **NEW DELHI 110030** 8800465156

Biological Reference Interval Test Report Status Results Units **Final**

Pus cells	Pus in the stool is an indication of infection	
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis	
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.	
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.	
Charcot-Leyden crystal	Parasitic diseases.	
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.	
Frank blood	Bleeding in the rectum or colon.	
Occult blood	Occult blood indicates upper GI bleeding.	
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.	
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up	
	in stool when there is inflammation or infection.	
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.	
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.	

ADDITIONAL STOOL TESTS:

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to 4. overuse of broad spectrum antibiotics which alter the normal GI flora.
- 5. Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria fungi virus parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery 6. diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr.Miral Gajera Consultant Pathologist



Page 19 Of 21



Email: customercare.ahmedabad@agilus.in





CODE/NAME & ADDRESS : C000138364 ACCESSION NO : **0321WG001445** AGE/SEX : 31 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRANM291291321 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/07/2023 08:55:50

DELHI

NEW DELHI 110030

ABHA NO : REPORTED : 10/07/2023 17:59:14

8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM

T3	135.60	80.0 - 200.0	ng/dL
METHOD: ECLIA			
T4	8.10	5.10 - 14.10	μg/dL
METHOD: ECLIA			

TSH (ULTRASENSITIVE) 2.260 0.270 - 4.200 μΙU/mL

METHOD : ECLIA

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

Dr.Miral Gajera Consultant Pathologist



Page 20 Of 21

View Details





Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Guirat, India





REF. DOCTOR: SELF PATIENT NAME: PRANAVKUMAR S. RANA

CODE/NAME & ADDRESS: C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO: 0321WG001445

PATIENT ID : PRANM291291321

CLIENT PATIENT ID: ABHA NO

AGE/SEX DRAWN

RECEIVED: 08/07/2023 08:55:50

:31 Years

REPORTED: 10/07/2023 17:59:14

Test Report Status Results Biological Reference Interval Units **Final**

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII,

Dr.Miral Gajera Consultant Pathologist





Page 21 Of 21



Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Guirat, India

